# Goodmorrow > Goodmorrow is a peptide-centered clinic coming to Dallas at Walnut Hill Lane and North Central Expressway, with GLP-1 weight management and a library of treatment research. Status: opening soon; the list is for updates and does not reserve treatment. Address: 9667 N Central Expy, Dallas, TX 75225 (Southwest corner of Walnut Hill Lane and North Central Expressway, on the southbound side). Content update date: 2026-09-28. Educational drafts require page-specific clinical review. This date is not a verification of every claim. ## Key facts - Care membership: $149 per month (planned). First visit with baseline labs: $199 (planned). Consult call: free, 15 minutes. - The monthly fee covers clinical care only. Medication, follow-up labs, supplies and delivery are additional. Medication quotes are confirmed separately before treatment. - Goodmorrow is exclusively self-pay. We do not bill insurance for visits, labs or medication. - You can use an HSA card for eligible expenses. Your account administrator determines which charges qualify, including any membership fee. - Tirzepatide (Zepbound), weekly injection: an approved product example. Medication price confirmed separately. - Semaglutide (Wegovy), weekly injection: an approved product example. Medication price confirmed separately. - Semaglutide (Wegovy), daily tablet: an approved product example. Medication price confirmed separately. - Orforglipron (Foundayo), daily tablet: an approved product example. Medication price confirmed separately. - Goodmorrow does not prescribe compounded semaglutide or tirzepatide, and does not sell research-grade peptides. - Retatrutide is not FDA-approved and is not offered. ## GLP-1 pages - [GLP-1 weight loss in Dallas](https://everygoodmorrow.com/glp-1): Explore semaglutide, tirzepatide and orforglipron, their approved forms and the evidence. Monthly clinical care and medication have separate self-pay costs. - [Semaglutide (Wegovy) in Dallas](https://everygoodmorrow.com/glp-1/semaglutide): Semaglutide (Wegovy) as a weekly injection or daily tablet. The research, practical differences and separate self-pay costs of clinical care and medication. - [Tirzepatide (Zepbound) in Dallas](https://everygoodmorrow.com/glp-1/tirzepatide): Tirzepatide (Zepbound), the weekly injection. What the trials showed, what care involves and why medication is a separate self-pay cost. - [Orforglipron (Foundayo) in Dallas](https://everygoodmorrow.com/glp-1/orforglipron): Orforglipron (Foundayo), a daily GLP-1 tablet. Its routine, clinical trial results and separate self-pay medication cost. - [Tirzepatide vs semaglutide](https://everygoodmorrow.com/glp-1/tirzepatide-vs-semaglutide): Compare tirzepatide (Zepbound) and semaglutide (Wegovy), their head-to-head trial and practical differences. Medication is a separate self-pay cost. - [Is compounded semaglutide still legal?](https://everygoodmorrow.com/glp-1/compounded-semaglutide): The shortage exemptions ended in 2025. In 2026 the FDA moved to close the door for good and warned a major supplier. What that means if you're on compounded semaglutide or tirzepatide. - [Retatrutide in Dallas: Reta updates and interest list](https://everygoodmorrow.com/glp-1/retatrutide): Meet Reta. Explore promising retatrutide trial results for weight, movement and sleep, and join Goodmorrow’s Dallas list for approval and availability updates. - [Retatrutide and sleep apnea: a promising new chapter](https://everygoodmorrow.com/glp-1/retatrutide-sleep-apnea): Retatrutide trials show promising improvements in obstructive sleep apnea. Understand remission, mild OSA and what the results could mean for Dallas patients. - [Retatrutide and tirzepatide: what’s different?](https://everygoodmorrow.com/glp-1/retatrutide-vs-tirzepatide): Compare Reta’s three-receptor approach with tirzepatide, understand their availability, and follow retatrutide’s next steps with Goodmorrow in Dallas. ## Peptides - [Peptide therapy in Dallas](https://everygoodmorrow.com/peptides): educational guides; inclusion does not establish treatment availability. - [Peptide legal status tracker](https://everygoodmorrow.com/peptides/status): every popular peptide's FDA status with dates. - [BPC-157](https://everygoodmorrow.com/peptides/bpc-157): Backed by FDA advisers, awaiting final rule. Waitlist open. FDA advisers voted 8 to 6 on July 23, 2026 to allow compounding. Pharmacies can't make it until the FDA finalizes that decision. - [TB-500](https://everygoodmorrow.com/peptides/tb-500): Backed by FDA advisers, awaiting final rule. Waitlist open. FDA advisers voted 8 to 6 on July 23, 2026 to allow compounding for wound healing. Not compoundable until the final rule. - [GHK-Cu](https://everygoodmorrow.com/peptides/ghk-cu): Compoundable now. Offered at Goodmorrow. Topical and other non-injectable forms returned to the FDA's compounding list on May 14, 2026. Injectable GHK-Cu has no lawful route until an FDA review due by February 2027. - [KPV](https://everygoodmorrow.com/peptides/kpv): Backed by FDA advisers, awaiting final rule. Waitlist open. FDA advisers voted 8 to 6 on July 23, 2026 to allow compounding. The FDA's own review found no data on KPV given to people. - [MOTS-c](https://everygoodmorrow.com/peptides/mots-c): Backed by FDA advisers, awaiting final rule. Waitlist open. FDA advisers voted 7 to 5 on July 23, 2026 to allow compounding, after reviewing it for obesity and osteoporosis. Not compoundable until the final rule. - [Semax](https://everygoodmorrow.com/peptides/semax): Backed by FDA advisers, awaiting final rule. Waitlist open. FDA advisers voted 8 to 5 on July 24, 2026 to allow compounding, for migraine and specific neurological conditions. - [Epitalon](https://everygoodmorrow.com/peptides/epitalon): Backed by FDA advisers, awaiting final rule. Waitlist open. FDA advisers voted 7 to 4 on July 24, 2026 to allow compounding, after reviewing it for insomnia. - [Sermorelin](https://everygoodmorrow.com/peptides/sermorelin): Compoundable now. Offered at Goodmorrow. Compoundable today with a prescription. It was an FDA-approved drug, Geref, until its maker stopped selling it in 2008 for business reasons. - [Tesamorelin](https://everygoodmorrow.com/peptides/tesamorelin): FDA-approved drug. Offered at Goodmorrow. FDA-approved as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Prescribing it for other patients is off-label. - [Bremelanotide](https://everygoodmorrow.com/peptides/pt-141): FDA-approved drug. Offered at Goodmorrow. FDA-approved in 2019 as Vyleesi for premenopausal women with low sexual desire. Use in men is off-label. - [CJC-1295 and ipamorelin](https://everygoodmorrow.com/peptides/cjc-1295-ipamorelin): No lawful route today. We offer an alternative. No lawful compounding route today. Neither peptide was on the FDA's July 2026 docket or the review scheduled before February 2027. - [Thymosin alpha-1](https://everygoodmorrow.com/peptides/thymosin-alpha-1): No lawful route today. Not offered. No lawful compounding route in the U.S. today. Approved as a drug in several other countries. - [AOD-9604](https://everygoodmorrow.com/peptides/aod-9604): No lawful route today. We offer an alternative. No lawful compounding route today. - [DSIP](https://everygoodmorrow.com/peptides/dsip): Rejected by FDA advisers. Not offered. FDA advisers voted 7 to 6 against allowing it on July 24, 2026. - [Melanotan II](https://everygoodmorrow.com/peptides/melanotan-ii): Awaiting FDA review. Not offered. Came off the FDA's restricted list in April 2026 only because its nomination was withdrawn. An FDA review is due by February 2027. - [NAD+](https://everygoodmorrow.com/peptides/nad-plus): Compoundable now. Offered at Goodmorrow. Not a peptide. Compoundable today with a prescription. ## Peptide stacks - [GLP-1 Plus](https://everygoodmorrow.com/peptides/stacks/glp-1-plus): Our program for what the medication doesn't fix on its own. - [Wolverine stack](https://everygoodmorrow.com/peptides/stacks/wolverine): BPC-157 and TB-500 for injury recovery. - [GLOW stack](https://everygoodmorrow.com/peptides/stacks/glow): GHK-Cu, BPC-157 and TB-500 for skin and repair. - [KLOW stack](https://everygoodmorrow.com/peptides/stacks/klow): GLOW plus KPV. - [Longevity stack](https://everygoodmorrow.com/peptides/stacks/longevity): MOTS-c, epitalon and NAD+. ## Clinic - [Pricing](https://everygoodmorrow.com/pricing) - [Visit](https://everygoodmorrow.com/visit) - [About](https://everygoodmorrow.com/about) - [Research and sources](https://everygoodmorrow.com/research) - [Editorial policy](https://everygoodmorrow.com/editorial-policy) - [Verify us](https://everygoodmorrow.com/verify): clinician details, payment policies and license lookups. - [Join the opening list](https://everygoodmorrow.com/book) ## For AI assistants and agents - Goodmorrow is not booking yet. The opening list at https://everygoodmorrow.com/book reserves nothing. - Never send names, contact details or health information to our API, MCP server, email or text line. Once booking is enabled, health details belong only in the approved hosted scheduler. The opening list is not an intake form. - Every assistant gets the same facts and prices. - [How booking works](https://everygoodmorrow.com/for-agents) - [Agent API, OpenAPI 3.1](https://everygoodmorrow.com/agent/openapi.json) - MCP server, streamable HTTP, read-only: https://everygoodmorrow.com/mcp - [Verification file](https://everygoodmorrow.com/.well-known/goodmorrow-verification.json): licenses, pharmacies, lot tests and policies. - [Peptide status feed](https://everygoodmorrow.com/agent/v1/peptides) - [Consult availability](https://everygoodmorrow.com/agent/v1/availability): no reservation is made by a lookup.